8,228 Shares in United Therapeutics Corporation $UTHR Purchased by Headlands Technologies LLC

Posted by Stanley Muller on Aug 31st, 2026

Headlands Technologies LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 8,228 shares of the biotechnology company’s stock, valued at approximately $4,458,000.

Other hedge funds have also bought and sold shares of the company. Arjuna Capital grew its holdings in United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC lifted its holdings in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC lifted its holdings in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares during the last quarter. Meeder Advisory Services Inc. boosted its position in shares of United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance boosted its position in shares of United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after purchasing an additional 27 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on UTHR. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Royal Bank Of Canada dropped their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

Read Our Latest Stock Report on United Therapeutics

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $517.28, for a total transaction of $4,914,160.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $167,827,875.04. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 404,575 shares of company stock valued at $216,652,640 over the last quarter. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

Shares of UTHR opened at $515.46 on Monday. The company has a market cap of $22.11 billion, a price-to-earnings ratio of 18.44, a P/E/G ratio of 1.75 and a beta of 0.59. The business’s fifty day simple moving average is $530.46 and its two-hundred day simple moving average is $539.16. United Therapeutics Corporation has a 12 month low of $303.08 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.41 earnings per share. As a group, research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Company Profile

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.